Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer
Molecular Oncology · 2026-04 · 20 (4) · 981-994
DOI: 10.1002/1878-0261.70170 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 27.11.2025. Verfasst von Kristin Løge Aanestad und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Stavanger University Hospital, Norway. Hauptthemen laut MEDLINE: Breast Neoplasms, Circulating Tumor DNA, Neoplasm Recurrence, Local, Early Detection of Cancer. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sparebankstitelsen SR-bank, Helse Vest.
Abstract (Originalsprache)
Breast cancer is known for late recurrences, yet current follow‐up lacks radiological or blood‐based monitoring for systemic relapse. This study evaluated circulating tumor DNA (ctDNA) monitoring for early detection of systemic relapse after curative treatment. In this case–control study of 70 patients with operable breast cancer (35 with relapse and 35 without relapse), blood samples were collected every 6–12 months during a median 8.3‐year follow‐up. ctDNA was analyzed by targeted DNA sequencing using Oncomine™ Breast cfDNA Research Assay v2, and results were compared to genetic analysis of tumor and metastasis biopsies. ctDNA was detected at relapse in 19 of 35 (54%) patients with disease relapse and preceded clinical or radiological relapse detection in 17, with a median lead time of 10.3 months. In 13 (68%) patients, there was concordance with tumor mutations, and in seven patients, there was also concordance with metastasis. Among the relapse‐free patients, seven were ctDNA‐positive postsurgery, and only one of them had a match among the tumor variants. These findings suggest serial ctDNA analysis may enable earlier detection of systemic relapse in patients with operable breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Stavanger University Hospital, Norway.
- Department of Research, Stavanger University Hospital, Norway.
- European Liquid Biopsy Society (ELBS), Hamburg, Germany.
- Hormone Laboratory, Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway.
- Department of Clinical Science, University of Bergen, Norway.
- Department of Pathology, Stavanger University Hospital, Norway.
ORCID-Profile: Kristin Løge Aanestad, Oddmund Nordgård
Förderung
- Sparebankstitelsen SR-bank
- Helse Vest
Zitieren
APA
Aanestad, K. L., Austdal, M., Nordgård, O., Mellgren, G., Oltedal, S., Austbø, M. L., Vignes, Y. H., Helland, T., Jonsdottir, K., Lende, T. H., Janssen, E. A. M., Gilje, B., Tjensvoll, K., & PBCB study group (2026). Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer. Molecular Oncology, 20(4), 981-994. https://doi.org/10.1002/1878-0261.70170
Vancouver
Aanestad KL, Austdal M, Nordgård O, Mellgren G, Oltedal S, Austbø ML, et al. Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer. Molecular Oncology. 2026;20(4):981-994. doi:10.1002/1878-0261.70170
BibTeX
@article{Aanestad2026,
author = {Aanestad, Kristin Løge and Austdal, Marie and Nordgård, Oddmund and Mellgren, Gunnar and Oltedal, Satu and Austbø, Marie L and Vignes, Ylva H and Helland, Thomas and Jonsdottir, Kristin and Lende, Tone H and Janssen, Emilius A M and Gilje, Bjørnar and Tjensvoll, Kjersti and PBCB study group, PBCB study group},
title = {Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer},
journal = {Molecular Oncology},
year = {2026},
volume = {20},
number = {4},
pages = {981--994},
doi = {10.1002/1878-0261.70170}
}
EUVIMED